PharmGen Science, Inc.

KSE 004720.KS

PharmGen Science, Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 28.75 M

PharmGen Science, Inc. Cash and Short-Term Investments is USD 28.75 M for the year ending December 31, 2023, a 83.02% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

PharmGen Science, Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 15.71 M, a -45.10% change year over year.
PharmGen Science, Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 28.61 M, a 2.37% change year over year.
PharmGen Science, Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 27.95 M, a 103.62% change year over year.
PharmGen Science, Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 13.73 M, a -66.58% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KSE: 004720.KS

PharmGen Science, Inc.

CEO	Lee Seung-Yeol
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	50, Jeyakgongdan 2-gil
Employees	248
Sector	Healthcare
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It offers prescription drugs, OTC drugs, health food, and cosmetics. It offers its products in the form of tablet, hard capsule, granule and ointment, syrups, and suspension forms. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1961 and is headquartered in Hwaseong, South Korea.

Key trends

Past 5 years